Endocyte

-$0.01 (-0.04%) Today
$0.00 (0.00%) As of 8:00 PM UTC after-hours

Why Robinhood?

You can watch Endocyte and buy or sell other stocks, options, and ETFs commission-free!

About ECYT

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug.

CEO
Michael A. Sherman, MBA
Employees
—
Headquarters
West Lafayette, Indiana
Founded
1995

ECYT Key Statistics

Market cap
1.95B
Price-Earnings ratio
—
Dividend yield
—
Average volume
1.68M
High today
—
Low today
—
Open price
—
Volume
0.00
52 Week high
$24.00
52 Week low
$2.81
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure